Q3155610 (Q3155610): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): The project brings together basic and clinical researchers (from various groups and centers), and the sponsorship of a biotechnology company (Janssen-Diagnostics-BVBA), with the overall objective of assessing whether the repertoire of KIR/HLA-class-I interactions that guide education and regulate the role of NK cells has an impact on tumor development and spread, as well as on the response to treatment and progression-free survival (SPL) and ove...) |
||||||||||||||
| Property / summary | |||||||||||||||
The project brings together basic and clinical researchers (from various groups and centers), and the sponsorship of a biotechnology company (Janssen-Diagnostics-BVBA), with the overall objective of assessing whether the repertoire of KIR/HLA-class-I interactions that guide education and regulate the role of NK cells has an impact on tumor development and spread, as well as on the response to treatment and progression-free survival (SPL) and overall (SG) of patients with three types of cancer (skinaneous melanoma and bladder and ovarian carcinomas). To this end, the following specific objectives shall be addressed: 1) Analyse the KIR receptor genotype and its class-I HLA ligands (HLA-A, -B and -C) using PCR-SSP and Luminex, as well as the expression of KIR receptors in peripheral blood NK and T cells by cytometry, in cancer patients and in healthy controls; (2) Determine the prognostic value for PFS and OS, as well as the predictive value of treatment effectiveness, of monitoring circulating tumor cells (CTCs) tested in peripheral blood by CellSearch (Veridex) method, before and after treatment; 3) To relate the repertoire of KIR/HLA interactions and the expression of KIR in peripheral blood cells, with the clinical-biological peculiarities of each type of cancer, the presence/frequency of CTCs or metastases and survival; and 4) Conduct functional trials of cytotoxicity and release of granules, versus K562 and tumor lines, in selected patients/controls, aimed at demonstrating the potential relationships between the KIR/HLA-I genotype and the protection or predisposition to metastatic cancer development or spread. 90 patients will be studied for each type of cancer (n=270), all at intermediate/high risk of progression or metastasis. (English) | |||||||||||||||
| Property / summary: The project brings together basic and clinical researchers (from various groups and centers), and the sponsorship of a biotechnology company (Janssen-Diagnostics-BVBA), with the overall objective of assessing whether the repertoire of KIR/HLA-class-I interactions that guide education and regulate the role of NK cells has an impact on tumor development and spread, as well as on the response to treatment and progression-free survival (SPL) and overall (SG) of patients with three types of cancer (skinaneous melanoma and bladder and ovarian carcinomas). To this end, the following specific objectives shall be addressed: 1) Analyse the KIR receptor genotype and its class-I HLA ligands (HLA-A, -B and -C) using PCR-SSP and Luminex, as well as the expression of KIR receptors in peripheral blood NK and T cells by cytometry, in cancer patients and in healthy controls; (2) Determine the prognostic value for PFS and OS, as well as the predictive value of treatment effectiveness, of monitoring circulating tumor cells (CTCs) tested in peripheral blood by CellSearch (Veridex) method, before and after treatment; 3) To relate the repertoire of KIR/HLA interactions and the expression of KIR in peripheral blood cells, with the clinical-biological peculiarities of each type of cancer, the presence/frequency of CTCs or metastases and survival; and 4) Conduct functional trials of cytotoxicity and release of granules, versus K562 and tumor lines, in selected patients/controls, aimed at demonstrating the potential relationships between the KIR/HLA-I genotype and the protection or predisposition to metastatic cancer development or spread. 90 patients will be studied for each type of cancer (n=270), all at intermediate/high risk of progression or metastasis. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The project brings together basic and clinical researchers (from various groups and centers), and the sponsorship of a biotechnology company (Janssen-Diagnostics-BVBA), with the overall objective of assessing whether the repertoire of KIR/HLA-class-I interactions that guide education and regulate the role of NK cells has an impact on tumor development and spread, as well as on the response to treatment and progression-free survival (SPL) and overall (SG) of patients with three types of cancer (skinaneous melanoma and bladder and ovarian carcinomas). To this end, the following specific objectives shall be addressed: 1) Analyse the KIR receptor genotype and its class-I HLA ligands (HLA-A, -B and -C) using PCR-SSP and Luminex, as well as the expression of KIR receptors in peripheral blood NK and T cells by cytometry, in cancer patients and in healthy controls; (2) Determine the prognostic value for PFS and OS, as well as the predictive value of treatment effectiveness, of monitoring circulating tumor cells (CTCs) tested in peripheral blood by CellSearch (Veridex) method, before and after treatment; 3) To relate the repertoire of KIR/HLA interactions and the expression of KIR in peripheral blood cells, with the clinical-biological peculiarities of each type of cancer, the presence/frequency of CTCs or metastases and survival; and 4) Conduct functional trials of cytotoxicity and release of granules, versus K562 and tumor lines, in selected patients/controls, aimed at demonstrating the potential relationships between the KIR/HLA-I genotype and the protection or predisposition to metastatic cancer development or spread. 90 patients will be studied for each type of cancer (n=270), all at intermediate/high risk of progression or metastasis. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 15:25, 12 October 2021
Project Q3155610 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3155610 in Spain |
Statements
46,000.0 Euro
0 references
57,500.0 Euro
0 references
80.0 percent
0 references
1 January 2014
0 references
31 March 2017
0 references
FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)
0 references
37°59'32.57"N, 1°7'49.94"W
0 references
30030
0 references
El proyecto reúne investigadores básicos y clínicos (de diversos grupos y centros), y el patrocinio de una empresa biotecnológica (Janssen-Diagnostics-BVBA), con el objetivo general de evaluar si el repertorio de interacciones KIR/HLA-clase-I que guían la educación y regulan la función de las células NK, tiene repercusión en el desarrollo y diseminación tumoral, así como en la respuesta al tratamiento y en la supervivencia libre de progresión (SPL) y global (SG) de pacientes con tres tipos de cáncer (melanoma cutáneo y carcinomas de vejiga y ovario). Para ello, se abordarán los siguientes objetivos específicos: 1) Analizar el genotipo de receptores KIR y el de sus ligandos HLA clase-I (HLA-A, -B y -C) mediante PCR-SSP y Luminex, así como la expresión de los receptores KIR en células NK y T de sangre periférica mediante citometría, en pacientes con cáncer y en controles sanos; 2) Determinar el valor pronóstico sobre la SLP y SG, así como el valor predictivo sobre la eficacia del tratamiento, de la monitorización de células tumorales circulantes (CTCs) analizadas en sangre periférica mediante método CellSearch (Veridex), antes y después del tratamiento; 3) Relacionar el repertorio de interacciones KIR/HLA y la expresión de KIR en células de sangre periférica, con las peculiaridades clínico-biológicas de cada tipo de cáncer, la presencia/frecuencia de CTCs y/o metástasis y la supervivencia; y 4) Realizar ensayos funcionales de citotoxicidad y liberación de gránulos, frente a K562 y líneas tumorales, en pacientes/controles seleccionados, dirigidos a demostrar las potenciales relaciones entre el genotipo KIR/HLA-I y la protección o predisposición al desarrollo y/o diseminación metastásica del cáncer. Se estudiarán 90 pacientes para cada tipo de cáncer (n=270), todos con riesgo intermedio/alto de progresión y/o metástasis. (Spanish)
0 references
The project brings together basic and clinical researchers (from various groups and centers), and the sponsorship of a biotechnology company (Janssen-Diagnostics-BVBA), with the overall objective of assessing whether the repertoire of KIR/HLA-class-I interactions that guide education and regulate the role of NK cells has an impact on tumor development and spread, as well as on the response to treatment and progression-free survival (SPL) and overall (SG) of patients with three types of cancer (skinaneous melanoma and bladder and ovarian carcinomas). To this end, the following specific objectives shall be addressed: 1) Analyse the KIR receptor genotype and its class-I HLA ligands (HLA-A, -B and -C) using PCR-SSP and Luminex, as well as the expression of KIR receptors in peripheral blood NK and T cells by cytometry, in cancer patients and in healthy controls; (2) Determine the prognostic value for PFS and OS, as well as the predictive value of treatment effectiveness, of monitoring circulating tumor cells (CTCs) tested in peripheral blood by CellSearch (Veridex) method, before and after treatment; 3) To relate the repertoire of KIR/HLA interactions and the expression of KIR in peripheral blood cells, with the clinical-biological peculiarities of each type of cancer, the presence/frequency of CTCs or metastases and survival; and 4) Conduct functional trials of cytotoxicity and release of granules, versus K562 and tumor lines, in selected patients/controls, aimed at demonstrating the potential relationships between the KIR/HLA-I genotype and the protection or predisposition to metastatic cancer development or spread. 90 patients will be studied for each type of cancer (n=270), all at intermediate/high risk of progression or metastasis. (English)
12 October 2021
0 references
Murcia
0 references
Identifiers
PI13_02297
0 references